ALLograft INformation EXchange (ALLINEX): Standard care versus standard care plus access to the ALLINEX website

ALLograft INformation EXchange (ALLINEX) - phase three: A randomised pilot study of standard care versus standard care plus access to the ALLINEX website

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN33172094

Enrollment

Registered

2012-03-16

Start date

2012-01-18

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: National Cancer Research Network

Interventions

Intervention (access to website) plus standard care versus standard care. Consenting patients will complete baseline measures prior to randomisation. Participation time is twelve weeks. Consultation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Having undergone allogeneic HSCT 2. Under specialist HSCT care 3. English literate 4. Aged 18 or over 5. Access to the internet Target Gender: Male & Female ; Lower Age Limit 18 no age limit or unit specified

Exclusion criteria

Exclusion criteria: 1. Unable to provide informed consent to participate 2. Have cognitive impairment or communication difficulties which are incompatible with the study 3. Participation in the study is judged to be inappropriate on clinical grounds

Design outcomes

Primary

Measure	Time frame
Feasibility and acceptability - Establish feasibility and acceptability of a specifically designed website as an adjunct to routine measured at 12 weeks	—

Secondary

Measure	Time frame
1. Patient behaviour - Demonstrate change in patient behaviour 2. Patient well-being - Enhancement of patient well-being compared to standard care group. Measured at 6 weeks	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026